Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Elisabetta Bernardinello"'
Autor:
Luisa Cavalletto, Elisabetta Bernardinello, Giulio Diodati, Enzo Raise, Angelo Gatta, Liliana Chemello
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 9, Iss 4, Pp 173-181 (2008)
The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV). This antiviral schedule can in fact avoid the three fold mort
Externí odkaz:
https://doaj.org/article/18b90606b97b4752a976c22cffbd3964
Autor:
Enzo Raise, Giulio Diodati, Elisabetta Bernardinello, Angelo Gatta, Liliana Chemello, Luisa Cavalletto
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 9, Iss 4, Pp 173-181 (2008)
The current standard of care for the treatment of chronic hepatitis C virus (HCV) infection is combination therapy with Peg-interferon (IFN) alpha-2a or alpha-2b type plus ribavirin (RBV). This antiviral schedule can in fact avoid the three fold mort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbebd2276ba4812ff5b31bbf1434841
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/235
https://journals.seedmedicalpublishers.com/index.php/FE/article/view/235
Autor:
Enrico N. De Toni, Liliana Chemello, Giulia Perini, Cristina Bergamelli, Franco Del Piccolo, Piero Amodio, Angelo Gatta, Elisabetta Bernardinello, Luisa Cavalletto, R Costanzo, Federica Bergamaschi, Stefano Zanone Poma, Daniela Mapelli
Publikováno v:
Journal of Affective Disorders. 84:93-98
This study is aim to investigate concurrent long-term psychiatric, cognitive and neurophysiological measures of alpha-IFN neurotoxicity in the treatment of chronic viral hepatitis.Twenty patients with HCV hepatitis were enrolled while treated with al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b19719c1aa1fb99c6e75bb8eba2fd91
https://doi.org/10.1016/j.jad.2004.09.004
https://doi.org/10.1016/j.jad.2004.09.004
Autor:
Carlo Donada, Alfredo Alberti, F. Belussi, Patrizia Pontisso, Elisabetta Bernardinello, Liliana Chemello, Pietro Casarin, Luisa Cavalletto, Filippo Marino, Angelo Gatta
Publikováno v:
Journal of Hepatology. 33:128-134
Background/Aims: In chronic hepatitis C, interferon-alpha (α-IFN) and ribavirin combination therapy improves sustained response compared to α-IFN monotherapy, both in naive patients and in previous α-IFN relapsers, but the efficacy of such therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce5fc9f54e8716ad19a8475956110853
https://doi.org/10.1016/s0168-8278(00)80169-5
https://doi.org/10.1016/s0168-8278(00)80169-5
Autor:
L Cavalletto, F. Urban, Alfredo Alberti, Patrizia Pontisso, Pietro Casarin, Attilio Cecchetto, Elisabetta Bernardinello, Angelo Gatta, F Cavinato, S. Boccato, Liliana Chemello
Publikováno v:
Journal of Viral Hepatitis. 6:321-327
Standard treatment for chronic hepatitis C currently consists of 3-6 million units (MU) of interferon-alpha (IFN-alpha) given thrice weekly (t.i.w.) for 12 months, obtaining rates of sustained response (SR) that usually do not exceed 15-25%. Some rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::608d1f537bebd4c27f61add80a80e2fd
https://doi.org/10.1046/j.1365-2893.1999.00165.x
https://doi.org/10.1046/j.1365-2893.1999.00165.x
Autor:
Alfredo Alberti, Piero Casarin, Patrizia Pontisso, Carlo Donada, Luisa Cavalletto, Flavia Urban, P. Bonetti, Elisabetta Bernardinello, Liliana Chemello
Publikováno v:
Gastroenterology. 113:1654-1659
Approximately 75%-85% of patients with chronic hepatitis C virus (HCV) infection do not have a sustained response when treated with interferon (IFN). Limited information exists on the efficacy of retreatment with IFN alone in these patients. The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d61ed02ebc6443c9310ed3cb6b9f0adb
https://doi.org/10.1053/gast.1997.v113.pm9352869
https://doi.org/10.1053/gast.1997.v113.pm9352869
Autor:
Liliana Chemello, F. Belussi, Alfredo Alberti, Patrizia Pontisso, Elisabetta Bernardinello, Luisa Cavalletto, Emanuela Silvestri
Publikováno v:
International Hepatology Communications. 3:237-243
Eight Italian patients with chronic hepatitis C were treated intravenously with natural β-interferon (β-IFN) to assess primary biochemical and virological response and also to investigate the relation to the genotype of infecting HCV. Each patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96df6e5ab11dfb532f190f2b4a317264
https://doi.org/10.1016/0928-4346(94)00185-8
https://doi.org/10.1016/0928-4346(94)00185-8
Autor:
E Belussi, P. Bonetti, C. Casarin, Pietro Casarin, Liliana Chemello, Alfredo Alberti, Patrizia Pontisso, Luisa Cavalletto, Elisabetta Bernardinello, Carlo Donada, M. Frezza, Franco Noventa
Publikováno v:
Journal of Viral Hepatitis. 2:91-96
Three main patterns of response are seen when interferon-alpha (IFN-alpha) is used for the treatment of chronic hepatitis C: 1 sustained response with alanine-aminotransferase (ALT) normalization that is maintained after cessation of therapy, with or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcaa9333f2d8ccc098072a3e70bbac4c
https://doi.org/10.1111/j.1365-2893.1995.tb00012.x
https://doi.org/10.1111/j.1365-2893.1995.tb00012.x
Autor:
Eugenio Ragazzi, Carlo Virgilio Luigi Costa, Liliana Chemello, Luisa Cavalletto, Antonella Bertazzo, Stefano Comai, Elisabetta Bernardinello
Publikováno v:
Pharmacological research. 63(1)
The currently recommended therapy for chronic hepatitis C (HCV) is a combination of pegylated interferon-alpha (PEG-IFN alpha) and ribavirin. Psychiatric disorders, including depression, are frequent in HCV patients under therapy. We investigated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1bdacf3693f8299d4ba7fb941b5eb67
https://pubmed.ncbi.nlm.nih.gov/20940053
https://pubmed.ncbi.nlm.nih.gov/20940053
Autor:
Giorgio Fassina, Elisabetta Bernardinello, Angelo Gatta, Liliana Chemello, Patrizia Pontisso, Flavia Bortolotti, Luisa Cavalletto, Alessandra Biasiolo, N. Tono, C Caberlotto, L. Beneduce, Santina Quarta
Publikováno v:
Journal of viral hepatitis. 15(4)
About 30% of the patients with chronic hepatitis develop a progressive liver disease and one of the most intriguing issues is the detection of noninvasive markers for fibrosis stage and disease progression. High levels of squamous cell carcinoma anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c953987fe46f7d1e061145fe396a50b
https://pubmed.ncbi.nlm.nih.gov/18248333
https://pubmed.ncbi.nlm.nih.gov/18248333